3-氟-4-甲基苯甲酸甲酯 | 87808-48-8

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氟-4-甲基苯甲酸甲酯
• 英文名称: methyl 3-fluoro-4-methylbenzoate
• 英文别名: 4-methyl-3-fluorobenzoic acid methyl ester
• CAS: 87808-48-8
• 化学式: C₉H₉FO₂
• mdl: MFCD06203786
• 分子量: 168.168
• InChiKey: RAFFOVQBMRBRCS-UHFFFAOYSA-N

物化性质

• 沸点：
  222.1±28.0 °C(Predicted)
• 密度：
  1.137±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P264,P270,P301+P312,P330
• 危险性描述：
  H302,H315,H320,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 3-fluoro-4-methylbenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-fluoro-4-methylbenzoate
CAS number: 87808-48-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H9FO2
Molecular weight: 168.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氟-4-甲基苯甲酸甲酯 在 platinum(IV) oxide N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 氢气 、 sodium methylate 作用下， 以 甲醇 、 四氯化碳 、 乙酸乙酯 、 甲苯 为溶剂， 反应 115.0h， 生成 3-fluoro-4-{3-[2-(methoxyoxalyl-phenyl-amino)-pyridin-3-yl]-3-oxo-propyl}-benzoic acid methyl ester
  参考文献：
  名称：

  ADAMANTYL COMPOUNDS

  摘要：

  这项发明涉及JNK抑制剂及相应的用于抑制JNK和治疗JNK介导的疾病的方法、配方和组合物。该申请披露了如下所述的JNK抑制剂，其化学式如下： 其中变量如本文所定义。本文披露的化合物和组合物可用于调节JNK的活性并治疗与JNK活性相关的疾病。本文还披露了用于抑制JNK和治疗JNK介导的疾病等的方法和配方，以及用于制备上述化合物的过程和相应的组合物。

  公开号：

  US20120258982A1
• 作为产物：
  描述：

  对甲基苯甲酸甲酯 在 二氟代氙 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以50%的产率得到3-氟-4-甲基苯甲酸甲酯
  参考文献：
  名称：

  Rearrangement and radical mediated decarboxylation of trimethylsilyl benzoates using xenon difluoride

  摘要：

  在 CH2Cl2 或 C6F6 溶液中用二氟化氙处理三甲基硅基苯甲酸酯 1，会产生一种新的酯重排反应，并形成芳基氟甲酸酯 2：在 MeCN 溶液中观察不到重排反应，在该溶液中，主要产物是通过相应芳基形成的炔。

  DOI：

  10.1039/p19960000121

文献信息

• Solvolysis of 2-chloro-2(3,4-disubstituted) phenylpropanes: Validity of Hammett-Brown σ+ constants in assessing additive effects of substituents
  作者：Ahmed A. Taha

  DOI：10.1002/kin.20617

  日期：2012.8

  to depict such systems. The halogen substituents' extent of conformity with additivity reflected in their relative (kobsd/kcalcd) rate ratios is found to correlate with the steric size of substituents. Plots of rate ratios against Taft's steric factor of each halogen give a linear correlation coefficient of 0.994 for the 3‐halo substituents. The 3,4‐dimethyl substituents' relative rate ratio of 1.03

  这项研究的目的是测试扩展的Hammett-Brown方程log（k XX / k HH）=ρ + Σσ +的适用性，以描述令人满意的负电性含原子取代基的加和作用，已知该负电性取代基具有多种和多组分影响多取代苯的侧链反应。该方程式首次被用来关联取代基在2-氯-2-苯基丙烷（3b-3f）具有3 F，4 Me，3 Br，4 Me，3 I，4 Me，3 Me，4 Me或3 MeO，4 Me取代基。使用90％的丙酮水溶液作为溶剂，在288、298和308 K处滴定测定速率。发现这些取代基对母体枯基氯（2-氯-2-苯基丙烷）的溶剂分解速率和活化参数的测量加成效应与上述方程式具有很好的相关性。3b–3f的log（k XX / k HH）与先前针对Σσ +的研究中主要是二取代，三取代和单取代的枯基氯化物一起绘制的图给出0.990的线性相关系数，作为描述此类系统的方程有效性的量度。发现卤素取代基与它们的相对（k
• Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot–Marie–Tooth Type 2A Mouse Model
  作者：Sida Shen、Cristina Picci、Kseniya Ustinova、Veronick Benoy、Zsófia Kutil、Guiping Zhang、Maurício T. Tavares、Jiří Pavlíček、Chad A. Zimprich、Matthew B. Robers、Ludo Van Den Bosch、Cyril Bařinka、Brett Langley、Alan P. Kozikowski

  DOI：10.1021/acs.jmedchem.0c02210

  日期：2021.4.22

  we report the discovery of a new THQ-capped HDAC6i, termed SW-101 (1s), that possesses excellent HDAC6 potency and selectivity, together with markedly improved metabolic stability and druglike properties compared to SW-100 (1a). X-ray crystallography data reveal the molecular basis of HDAC6 inhibition by SW-101 (1s). Importantly, we demonstrate that SW-101 (1s) treatment elevates the impaired level

  组蛋白脱乙酰基酶6（HDAC6）是治疗神经退行性疾病的有希望的治疗靶标。SW-100（1a）是带有四氢喹啉（THQ）封端基团的基于苯基异羟肟酸酯的HDAC6抑制剂（HDAC6i），是一种高效且选择性强的HDAC6i，已证明在脆性X综合征和Charcot–Marie–的小鼠模型中有效2A型牙齿疾病（CMT2A）。在这项研究中，我们报告发现了一种新的被THQ封端的HDAC6i，称为SW-101（1s），与SW-100（1a）相比，HDAC6i具有出色的HDAC6效能和选择性，并具有明显改善的代谢稳定性和类似药物的特性。X射线晶体学数据揭示了SW-101（1s）。重要的是，我们证明了SW-101（1s）治疗可升高坐骨神经末梢中乙酰化α-微管蛋白的受损水平，抵消进行性运动功能障碍，并改善携带突变型MFN 2的CMT2A小鼠模型的神经性症状。这一结果预示着SW-101（1s）作为一种疾病缓解型HDAC6i的进一步发展。
• Fluorescent and NMR sensitive pH indicators
  申请人：The United States of America as represented by the Department of Health

  公开号：US05639906A1

  公开（公告）日：1997-06-17

  This invention relates to compositions and methods useful for measuring pH generally, and intracellular pH specifically, and, more particularly, to a new class of fluorescent and fluorinated (NMR sensitive) aromatic compounds having excitation emission wavelengths in the ultraviolet or or visible portions of the electromagnetic spectrum, useful as pH indicators, as well as fluorine containing analogs useful in NMR spectroscopic determinations.

  这项发明涉及用于测量pH值，特别是细胞内pH值的组合物和方法，更具体地说，是一种新型的含有荧光和氟化（对核磁共振敏感）的芳香化合物，其激发发射波长位于电磁谱的紫外或可见光部分，可用作pH指示剂，以及含有氟的类似物，在核磁共振光谱测定中非常有用。
• THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS
  申请人：AXFORD Jake

  公开号：US20140206661A1

  公开（公告）日：2014-07-24

  The present invention provides a compound of Formula (X) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种公式（X）的化合物或其药用盐；一种制造本发明化合物的方法及其治疗用途。本发明进一步提供了一种药物活性剂的组合物和一种药物组合物。
• [EN] AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS<br/>[FR] DÉRIVÉS AZA-INDOLIQUES UTILISÉS COMME INHIBITEURS DE MULTIPLES KINASES
  申请人：ORIBASE PHARMA

  公开号：WO2014102377A1

  公开（公告）日：2014-07-03

  The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.

  本发明涉及式(I)化合物和/或其药用可接受的增加盐、溶剂化物、对映异构体、非对映异构体，以及它们的混合物。因此，本发明的主题还包括式(I)化合物的制备、用途，特别是在抑制涉及多种疾病（如癌症或免疫系统疾病）的蛋白激酶方面的用途。